AMO Pharma

31 articles about AMO Pharma

• 

  Can a Pharma Drug Improve Autism Conditions?

  11/1/2018

  There are no treatments for autism, but that’s not stopping research into the development of therapies for core symptoms of autism spectrum disorder. This week, London-based AMO Pharma reported Phase II results from its investigational glycogen synthase kinase 3 (GSK3) beta inhibitor, AMO-02 (tid...

• AMO Pharma Receives FDA Orphan Drug Designation for AMO-04 in Treatment of Rett Syndrome

  6/13/2018

  U.S. Food and Drug Administration has granted Orphan Drug Designation to its investigational therapy AMO-04 for the treatment of Rett syndrome, a rare childhood neurodevelopmental disorder.

• AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome

  5/7/2018

  AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options, today announced initiation of patient recruitment in an interventional study of AMO-01, the company's investigational Ras-ERK pathway inhibitor, in the treatment of Phelan-McDermid syndrome.

• 

  AMO Pharma Sees Positive Results in Phase II Trials

  3/16/2018

  AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks.

• AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

  10/18/2017

  AMO Pharma presented positive interim analysis of data from the first cohort of its study of AMO-02 in congenital myotonic dystrophy.

• AMO Pharma Reports Update On Positive Interim Analysis For The First Cohort Of Phase IIa Congenital Myotonic Dystrophy Study

  9/25/2017

• AMO Pharma Receives FDA Orphan Drug Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

  7/27/2017

• AMO Pharma Enters Into Development And License Agreement With Numedicus Limited For Rett Syndrome Program

  7/20/2017

• AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

  5/30/2017

• AMO Pharma Presents Pre-Clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated With Fragile X Syndrome

  6/7/2016

• Joseph Horrigan Joins AMO Pharma As Chief Medical Officer

  4/18/2016